RADNOSTIX INC
Close on Oct 19, 2026
- Market cap
- $24.87M
- P/E (TTM)
- –
- Dividend yield
- –
About Radnostix
Industrial Instruments For Measurement, Display, and Control, SIC 3823
Radnostix Inc. manufactures radioisotope-based products for medical, industrial, and research uses. The company operates through five reportable business segments: Theranostics Products, Cobalt Products, Calibration & Reference Products, Medical Devices, and Fluorine Products. Its offerings include generic radiopharmaceuticals such as sodium iodide I-131, active pharmaceutical ingredients, radiochemicals, cobalt-60 sealed sources, imaging calibration standards, and lung ventilation medical devices. Radnostix serves radiopharmacies, clinical research organizations, contract development and manufacturing organizations, original equipment manufacturers, environmental laboratories, utilities, and the United States Department of Energy.
The company employs 45 individuals, including 44 full-time workers. It maintains operating facilities in Idaho, including a dedicated manufacturing site at Commerce Way, and holds licenses for a planned facility in Lea County, New Mexico. Radnostix distributes its products across all 50 United States and delivers to various international markets, including Canada, China, and overseas destinations. The text does not specify the location of its corporate headquarters.
Summary of the business section of Radnostix's latest annual report, written by StockData.
Company profile
Company
- Legal name
- RADNOSTIX INC
- Founded
- 1995
- Headquarters
- Idaho Falls, ID
- Address
- 4137 Commerce Circle 83401
- Phone
- (208) 524-5300
- Website
- radnostix.com
- Employees
- 45, Dec 31, 2025
- Industry
- Industrial Instruments For Measurement, Display, and Control
- Incorporated in
- Texas
- Fiscal year ends
- December 31
- Auditor
- Haynie & Company, Salt Lake City, Utah
Stock & identifiers
- Ticker
- INIS
- Exchange
- OTC
- IPO date
- Aug 14, 1997
- Shares outstanding
- 529M, Aug 10, 2026
- Public float
- $6.00M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- SEC CIK
- 1038277
- CUSIP
- 45972C102
- ISIN
- US45972C1027
- EIN
- 74-2763837
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Shahe Bagerdjian | Pres. & CEO, Director | 9,026,999 |
| W. Matthew Cox | Chief Financial Officer | 897,736 |
| Christopher G. Grosso | Director | 50,890,081 |
| Steve Laflin | Director | 9,543,166 |
| Robert Atcher | Director | 1,000,000 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Mr Bagerdjian | $1.48M | $2.05M | $172.70K | $200 | – |
| FY2025 Mr Laflin | $0 | $0 | $172.70K | $200 | – |
| FY2024 | $429.70K | $319.70K | $148.65K | $100 | – |
| FY2024 Former PEO | $0 | $0 | $148.65K | $100 | – |
| FY2024 Mr Bagerdjian | $429.70K | $319.70K | $148.65K | $100 | – |
| FY2024 Mr Laflin | $0 | $0 | $148.65K | $100 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 45 total employees, including 44 full-time employees.”
Corporate history
Events identified from SEC filings